Lupin: A Global Pharmaceutical Powerhouse Transforming Healthcare
Lupin Limited is one of India’s leading multinational pharmaceutical companies, recognized for its innovation, affordability, and commitment to quality healthcare. Founded in 1968 by Desh Bandhu Gupta, Lupin began as a small vitamin manufacturer and has evolved into a global healthcare giant operating in over 100 countries.
Lupin's diverse product portfolio spans generic and branded formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty drugs. The company holds a strong presence in critical therapeutic areas such as cardiovascular, diabetes, respiratory, central nervous system (CNS), gastrointestinal, and anti-infectives. It is also a prominent player in pediatric and women’s health segments.
A significant strength of Lupin lies in its robust research and development (R&D) capabilities. With state-of-the-art R&D centers across India and the U.S., Lupin continuously develops complex generics, biosimilars, and novel drug delivery systems. The company has made notable advances in inhalation therapy and complex injectables, setting new standards in patient care.
Globally, Lupin has secured a firm foothold in regulated markets like the U.S., Japan, and Europe, with the U.S. being its largest revenue contributor. Through strategic acquisitions, partnerships, and consistent innovation, Lupin continues to expand its global footprint and impact.
With a strong ethical foundation and sustainability-driven initiatives, Lupin is not just delivering medicines but also promoting access to affordable healthcare across the world. Its vision of “Building a healthier world” resonates in its actions, making it a trusted name in pharmaceuticals.